Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALESSE vs PROSTASCINT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol and levonorgestrel suppresses gonadotropin-releasing hormone (Gn RH) secretion from the hypothalamus, inhibiting pituitary release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby preventing ovulation. Additionally, it thickens cervical mucus, impeding sperm penetration, and alters endometrial receptivity.
PROSTASCINT is a murine monoclonal antibody fragment (capromab pendetide) conjugated to the chelating agent glycyl-tyrosyl-lysyl-diethylenetriaminepentaacetic acid (GYK-DTPA) and labeled with indium-111. It binds to the intracellular epitope of prostate-specific membrane antigen (PSMA) expressed on prostate epithelial cells and is used for imaging prostate cancer.
Prevention of pregnancy,Treatment of moderate acne vulgaris (in women ≥15 years who have achieved menarche and desire contraception),Contraception in women with heavy menstrual bleeding (off-label)
FDA-approved: Diagnostic imaging in patients with biopsy-proven prostate cancer who are at high risk for pelvic lymph node metastases or with rising PSA after local therapy,Off-label: None well-established
One tablet (ethinyl estradiol 20 mcg, levonorgestrel 0.1 mg) orally once daily at the same time each day for 21 days, followed by 7 days of placebo. For initiation, start on the first day of menstrual period or first Sunday after onset of menses.
5 m Ci (185 MBq) intravenously over 5 minutes, single dose.
Levonorgestrel: terminal half-life ~17-20 hours (range 11-25 hr). Ethinyl estradiol: biphasic; terminal half-life ~13-27 hours (mean ~17 hr). Clinical context: steady-state achieved within 5-7 days. The half-life supports once-daily dosing with at least 24-hour contraceptive coverage.
Terminal elimination half-life: 2.6 ± 0.7 days (requires 2 weeks for complete clearance; used for radioimmunodetection within 5–7 days post-injection)
Ethinyl estradiol is primarily metabolized by CYP3A4 and undergoes conjugation (glucuronidation and sulfation). Levonorgestrel is metabolized by CYP3A4 and reduction, with conjugation to glucuronide and sulfate conjugates.
Capromab pendetide is a monoclonal antibody fragment; metabolism is via catabolism to amino acids and small peptides. The indium-111 label is not metabolized and decays physically.
Renal: ethinyl estradiol (UE2) and levonorgestrel (LNG) metabolites primarily excreted in urine (UE2: ~40% as sulfate and glucuronide conjugates; LNG: ~25% as glucuronides). Fecal/biliary: ~40% (UE2) and ~45% (LNG) eliminated in feces via bile. Unchanged drug excretion is negligible.
Renal: ~90% (predominantly as intact tracer), Fecal: <5%
Levonorgestrel: 97-99% bound to albumin and sex hormone-binding globulin (SHBG). Ethinyl estradiol: 98-99% bound, primarily to albumin (98.5%), with minor binding to SHBG. Free fractions: LNG ~1%, UE2 ~1.0-1.5%.
~90% (binding to plasma proteins, likely immunoglobulins and albumin)
Levonorgestrel: Vd ~1.8 L/kg (range 1.5-2.0 L/kg). Ethinyl estradiol: Vd ~2.5-3.5 L/kg (mean ~2.9 L/kg). Indicates extensive tissue distribution, including target organs (ovaries, endometrium, breast). Not clinically adjusted for obesity.
5.5 L (not weight-adjusted; approximates intravascular space with slow distribution to extravascular tumor sites)
Oral: levonorgestrel ~95-100% (highly bioavailable). Ethinyl estradiol ~45-55% (first-pass metabolism reduces bioavailability; interindividual variability due to gut wall and hepatic conjugation). Both are prodrugs requiring hydrolysis for activity.
IV: 100% (not administered via other routes)
No specific GFR-based dose adjustments are recommended; however, use with caution in patients with renal impairment due to potential fluid retention and hypertension.
No specific dose adjustment recommended; caution in severe renal impairment (GFR <30 m L/min) due to potential radiation clearance delay.
Contraindicated in patients with severe hepatic disease (Child-Pugh class C) or active liver disease. In mild to moderate impairment (Child-Pugh A or B), use only if benefits outweigh risks; no specific dose reduction guidelines are available.
No specific adjustment for Child-Pugh class; caution in severe hepatic impairment due to altered clearance.
Approved for postmenarchal adolescents; same dosing as adults: one tablet orally once daily for 21 days followed by 7 days of placebo. No weight-based adjustments are recommended.
Safety and efficacy not established; not recommended for pediatric patients.
Not indicated for use in postmenopausal women; no specific geriatric dosing adjustments are necessary if used off-label, but consider increased risk of thrombotic events in older women.
No specific dose adjustment; follow standard adult dosing with consideration of renal function.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. The risk increases with age, particularly in women over 35 years, and with heavy smoking (≥15 cigarettes per day). Women over 35 who smoke should not use this medication.
Not applicable.
Increased risk of thromboembolic disorders (venous and arterial),Cigarette smoking increases risk of cardiovascular events, especially in women over 35,Hepatic neoplasia (benign and malignant),Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid metabolism effects,Headache/migraine,Depression,Uterine bleeding irregularities,Ocular lesions (e.g., retinal thrombosis),Carcinoma of the breast and reproductive organs (close monitoring in current or history of breast cancer)
Risk of hypersensitivity reactions, including anaphylaxis,Use of murine antibodies may cause human anti-mouse antibody (HAMA) response, potentially affecting subsequent murine antibody-based diagnostics or therapeutics,Radiation exposure from indium-111; risk of secondary malignancies,Limited data in patients with renal impairment
Breast cancer (current or history),Carcinoma of the endometrium or other estrogen-dependent neoplasia,Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Valvular heart disease with complications,Severe hypertension,Diabetes with vascular involvement,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known or suspected pregnancy,Active liver disease or impaired liver function,Undiagnosed abnormal uterine bleeding,Hypersensitivity to any component,Cigarette smoking in women over 35 years of age
Hypersensitivity to capromab pendetide, indium-111, or any component of the formulation,Pregnancy: potential fetal harm from radiation
No specific food restrictions. Grapefruit juice may slightly increase ethinyl estradiol levels but not clinically significant. High-fat meals do not affect absorption. Avoid excessive alcohol as it may impair compliance.
No known food interactions. Maintain adequate hydration; no dietary restrictions required.
Pregnancy category X. Use contraindicated in pregnancy. First trimester exposure associated with cardiovascular defects (e.g., VSD), neural tube defects, and cleft lip/palate. Second and third trimester exposure may cause fetal adrenal suppression, hepatic dysfunction, and virilization of female genitalia due to progestin component (levonorgestrel). Increased risk of ectopic pregnancy if conception occurs during use.
PROSTASCINT (indium-111 capromab pendetide) is a murine monoclonal antibody labeled with indium-111 used for imaging. No adequate human data on fetal risk. Animal studies are not available. The radiopharmaceutical component emits radiation; fetal radiation exposure may increase the risk of congenital anomalies and childhood malignancies. Use in pregnant women is contraindicated unless potential benefit outweighs risks. First trimester exposure poses highest risk of teratogenesis; second and third trimester exposure may increase risk of childhood cancer.
Excreted in breast milk. Levonorgestrel M/P ratio approximately 0.3–0.4. Small amounts of ethinyl estradiol present. May reduce milk production and quality due to estrogen component. Use only if benefit outweighs risk; consider alternative contraception. American Academy of Pediatrics considers it compatible with nursing.
Indium-111 is a radioactive isotope with a physical half-life of 2.8 days. Radioactive iodine may concentrate in breast milk. It is recommended to discontinue breastfeeding after administration. No M/P ratio available. To reduce radiation exposure to the infant, breastfeeding should be interrupted for a period based on the decay of indium-111 (typically at least 10 half-lives, i.e., 28 days). Pump and discard milk during this time.
Contraindicated. No dose adjustments apply as drug must be discontinued immediately if pregnancy suspected or confirmed. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) not relevant due to contraindication.
PROSTASCINT is contraindicated in pregnancy unless clearly needed. No pharmacokinetic data in pregnancy. Dose adjustment is not recommended as use should be avoided; if necessary, the minimum diagnostic activity should be used. Standard adult dose: 5 m Ci (0.5 mg antibody) intravenous. No adjustment for pregnancy-related pharmacokinetic changes due to lack of data.
ALESSE is a combined oral contraceptive (COC) containing ethinyl estradiol (20 mcg) and levonorgestrel (100 mcg). It is indicated for contraception and treatment of acne vulgaris in women aged ≥14. Monitor for thromboembolic events, especially in smokers >35 years. Assess for contraindications including migraines with aura, hypertension, and history of DVT/PE. Advise use of backup contraception if a pill is missed. Start on first day of menses or first Sunday after onset. Check BP at baseline and annually. Counsel on increased risk of VTE, especially in first year.
Prostascint (capromab pendetide) is a radiolabeled monoclonal antibody used for imaging prostate-specific membrane antigen (PSMA) in patients with prostate cancer. For optimal imaging, allow 72 hours post-injection for clearance of unbound antibody. Use with caution in patients with known murine protein allergy; pre-medicate with antihistamines if prior reaction. False-positive scans may occur in benign prostatic hyperplasia or inflammation. Ensure adequate hydration to promote renal excretion of the radiopharmaceutical.
Take one pill daily at the same time each day, even if you do not have sex.,Missed pill instructions: if late by <12 hours, take it as soon as remembered and continue schedule. If >12 hours, take missed pill (even if means taking two in one day) and use backup contraception for 7 days.,Possible side effects: nausea, breast tenderness, headache, breakthrough bleeding, especially in first 3 months.,Seek emergency care for signs of blood clot: leg pain/swelling, sudden chest pain, shortness of breath, severe headache, vision changes.,Do not smoke while on ALESSE, especially if over age 35, as it increases risk of serious cardiovascular events.,Inform your healthcare provider of all medications and supplements you take, as some (e.g., rifampin, anticonvulsants, St. John's wort) may reduce effectiveness.
This drug is a radioactive imaging agent that helps detect the spread of prostate cancer.,You will receive a single intravenous injection before your scan.,Drink plenty of water after the injection to help clear the radioactive material from your body.,Avoid close contact with pregnant women and young children for 24 hours after the scan.,Inform your doctor if you have had allergic reactions to mouse proteins or previous monoclonal antibody therapy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALESSE vs PROSTASCINT, answered by our medical review team.
ALESSE is a Estrogen/Progestin Combination Contraceptive that works by Combination of ethinyl estradiol and levonorgestrel suppresses gonadotropin-releasing hormone (Gn RH) secretion from the hypothalamus, inhibiting pituitary release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby preventing ovulation. Additionally, it thickens cervical mucus, impeding sperm penetration, and alters endometrial receptivity.. PROSTASCINT is a Radiopharmaceutical Diagnostic Agent that works by PROSTASCINT is a murine monoclonal antibody fragment (capromab pendetide) conjugated to the chelating agent glycyl-tyrosyl-lysyl-diethylenetriaminepentaacetic acid (GYK-DTPA) and labeled with indium-111. It binds to the intracellular epitope of prostate-specific membrane antigen (PSMA) expressed on prostate epithelial cells and is used for imaging prostate cancer.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALESSE and PROSTASCINT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALESSE is: One tablet (ethinyl estradiol 20 mcg, levonorgestrel 0.1 mg) orally once daily at the same time each day for 21 days, followed by 7 days of placebo. For initiation, start on the first day of menstrual period or first Sunday after onset of menses.. The standard adult dose of PROSTASCINT is: 5 m Ci (185 MBq) intravenously over 5 minutes, single dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALESSE and PROSTASCINT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALESSE is classified as Category C. Pregnancy category X. Use contraindicated in pregnancy. First trimester exposure associated with cardiovascular defects (e.g., VSD), neural tube defects, and cleft lip/palate. Seco. PROSTASCINT is classified as Category C. PROSTASCINT (indium-111 capromab pendetide) is a murine monoclonal antibody labeled with indium-111 used for imaging. No adequate human data on fetal risk. Animal studies are not a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.